

## SEQUENCE LISTING

<110> LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES (LFB)

<110> INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

<120> THERAPEUTIC PRODUCTS WITH ENHANCED ABILITY TO IMMUNOMODULATE CELL FUNCTIONS

<130> D21018

<150> EP 03/290 834

<151> 2003-04-03

<160> 6

<170> PatentIn version 3.2

<210> 1

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 1

gcagctcccc caaaggctgt g

21

<210> 2

<211> 21

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 2

ttggacagtg atggtcacag g

21

<210> 3

<211> 33

<212> DNA

<213> artificial

<220>

<223> Amplimer sense

<400> 3

tggatgatt ccctattaag tcatgggtat gtt

33

<210> 4

<211> 23

<212> DNA

<213> artificial

<220>

<223> Amplimer antisense

<400> 4

atcggatccc gactgaagat ctc

23

<210> 5

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB1/LFB2 antibody.

<400> 5

gcctccacca agggcccatc ggtcttcccc ctggcacccct cctccaagag cacctctggg 60  
 ggcacacgcgg ccctgggctg cctggtaag gactacttcc cgcgaaccgggt gacgggtgtcg 120  
 tggaaacttag ggcgcctgac cagccggctg cacaccttcc cggctgtcct acagtccctca 180  
 ggactctact ccctcagcag cgtggtgacc gtgccttcca gcagcttggg caccaggacc 240  
 tacatctgca acgtgaatca caagcccgac aacaccaagg tggacaagaa agttgagccc 300  
 aaatctttagt acaaaaactca cacatgcacca cctgtcccgac cacctgaact cctggggggga 360  
 ccgtcagtct tcctcttccc cccaaaaccc aaggacacccc tcacatgtctc ccggaccct 420  
 gaggtcacat gcgtgggttgt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480  
 tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540  
 agcacgtacc gtgtgggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600  
 gagtacaagt gcaagggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660  
 aaagccaaag ggcagccccc agaaccacag gtgtacacccc tgccccatc ccgggatgag 720  
 ctgaccaaga accaggttag cctgacctgc ctggtaaag gcttctatcc cagcgacatc 780  
 ggcgtggagt gggagagcaa tggcagccg gagaacaact acaagaccac gcctccctg 840  
 ctggactccg acggctcctt ctcttctac agcaagctca cctgtggacaa gagcaggtgg 900  
 cagcagggga acgtcttctc atgctccctg atgcatgagg ctctgcacaa ccactacacg 960  
 cagaagagcc tctccctgtc tccggtaaa 990

<210> 6

<211> 990

<212> DNA

<213> human

<220>

<223> Constant region of the heavy chain of LFB3 antibody.

<400> 6

gcctccacca agggcccatc ggtcttcccc ctggcacccct cctccaagag cacctctggg 60  
 ggcacacgcgg ccctgggctg cctggtaag gactacttcc cgcgaaccgggt gacgggtgtcg 120  
 tggaaacttag ggcgcctgac cagccggctg cacaccttcc cggctgtcct acagtccctca 180  
 ggactctact ccctcagcag cgtggtgacc gtgccttcca gcagcttggg caccaggacc 240  
 tacatctgca acgtgaatca caagcccgac aacaccaagg tggacaagag agttgagccc 300  
 aaatctttagt acaaaaactca cacatgcacca cctgtcccgac cacctgaact cctggggggga 360  
 ccgtcagtct tcctcttccc cccaaaaccc aaggacacccc tcacatgtctc ccggaccct 420  
 gaggtcacat gcgtgggttgt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480  
 tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540  
 agcacgtacc gtgtgggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600  
 gagtacaagt gcaagggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660  
 aaagccaaag ggcagccccc agaaccacag gtgtacacccc tgccccatc ccgggaggag 720  
 atgaccaaga accaggttag cctgacctgc ctggtaaag gcttctatcc cagcgacatc 780

gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccg 840  
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg 900  
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960  
cagaagagcc tctccctgtc cccggtaaa 990